Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Fineline Cube Aug 20, 2026
Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Fineline Cube Aug 20, 2026
Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Fineline Cube Aug 19, 2026
Company Deals

Hua Medicine Achieves Development Milestone for HuaTangNing with Bayer Agreement

Fineline Cube Aug 21, 2023

China-based Hua Medicine (HKG: 2552) has announced the achievement of a significant development milestone for...

Company Drug

MSD’s Welireg Meets Primary Endpoint in Phase III RCC Study but Misses OS Milestone

Fineline Cube Aug 21, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed that the ongoing Phase III study...

Company Deals

CARsgen Therapeutics Partners with Moderna to Combine CAR-T Therapy with mRNA Cancer Vaccine

Fineline Cube Aug 21, 2023

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced a collaboration agreement with US mRNA...

Company Deals

Simcere Pharmaceutical Group Secures Exclusive Rights to CMAB009 in China

Fineline Cube Aug 21, 2023

Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced that its subsidiary, Jiangsu Simcere Zaiming Pharmaceutical...

Company Deals

Ezisurg Medical Partners partners with Vathin for Global Disposable Endoscope strategic partnership

Fineline Cube Aug 21, 2023

Ezisurg Medical Co., Ltd has announced a strategic partnership with Hunan Vathin Medical Instrument Co.,...

Company

Fosun Pharma Adjusts Investment Allocation for 2022 Non-Public Offering Projects

Fineline Cube Aug 21, 2023

Fosun Pharma (SHA: 600196) has declared adjustments to the investment amounts for some of its...

Company Drug

HutchMed’s Sovleplenib Achieves Primary and Secondary Endpoints in ESLIM-01 Phase III Trial

Fineline Cube Aug 21, 2023

China-based biopharmaceutical company HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that the pivotal...

Company Drug

Grand Pharmaceutical Group Initiates Phase I Study for Sepsis Treatment APAD

Fineline Cube Aug 18, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the enrollment and dosing of the...

Company Drug

HutchMed’s Orpathys Receives Breakthrough Therapy Designation in China for Gastric Cancer

Fineline Cube Aug 18, 2023

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its MET inhibitor, Orpathys (savolitinib),...

Policy / Regulatory

Henan Leads 19-Province Alliance for Volume-Based Drug Procurement Tender

Fineline Cube Aug 18, 2023

A new inter-provincial alliance, led by Henan, has formed a 19-strong group to conduct a...

Company Drug

Humanwell Healthcare Initiates Phase IIa Clinical Study for IPF Drug HW021199

Fineline Cube Aug 18, 2023

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced the commencement of a Phase...

Company Drug

GSK’s RSV Vaccine Arexvy Launches in US Pharmacies Ahead of 2023/24 Season

Fineline Cube Aug 18, 2023

GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has announced that its respiratory syncytial virus...

Company Deals

Eyebright Medical Technology Plans GRD Listing on SIX Exchange to Raise RMB 1.4 Billion

Fineline Cube Aug 18, 2023

Eyebright Medical Technology Co., Ltd (SHA: 688050), a Beijing-based company specializing in ophthalmic medical devices,...

Company Drug

GC Biopharma Presents Data Showing Higher Thrombotic Risk with Roche’s Hemlibra

Fineline Cube Aug 18, 2023

South Korea’s GC Biopharma (KRX: 006280) has presented evidence suggesting that Roche’s (SWX: ROG) hemophilia...

Company Drug

Moderna Announces Immunogenicity of Updated COVID-19 Vaccine Against New Variants

Fineline Cube Aug 18, 2023

Moderna (NASDAQ: MRNA) has announced preliminary data indicating that an updated version of its SARS-CoV-2...

Company

Tigermed Establishes International Headquarters in Hong Kong to Accelerate Global Expansion

Fineline Cube Aug 18, 2023

China-based Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347) has announced the opening of...

Company Medical Device

NMPA Approves Rapid Medical Ltd’s Intracranial Thrombectomy Stent for Marketing

Fineline Cube Aug 18, 2023

The National Medical Products Administration (NMPA) has granted marketing approval to Rapid Medical Ltd for...

Company Drug

Luye Pharma Launches Rykindo in US, a First for Chinese CNS Drug

Fineline Cube Aug 18, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the official commercial operation of its Rykindo...

Company Deals

CytoMed Therapeutics Partners with CNK Therapeutics for CAR Gene Grafting Technology

Fineline Cube Aug 18, 2023

Singapore-based cell therapy developer CytoMed Therapeutics Ltd (NASDAQ: GDTC) has announced the signing of a...

Company Drug

CSPC Pharmaceutical Group Receives FDA Approval for NBL-028 Bispecific Antibody Clinical Study

Fineline Cube Aug 18, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...

Posts pagination

1 … 531 532 533 … 710

Recent updates

  • Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review
  • China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year
  • CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030
  • Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light
  • VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Company

CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030

Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.